From this recent FDA Safety Communication “UPDATE: Reports of Squamous Cell Carcinoma (SCC) in the Capsule Around Breast Implants” we get the following information about the new reporting system for cases of breast implant-associated lymphoma — the shorthand term for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL):
As of March 22, 2023, health care providers can submit case reports of SCC, various lymphomas, and any other cancers in the capsule around breast implants to the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and Epidemiology (PROFILE) Registry, a collaborative effort between the American Society of Plastic Surgeons (ASPS), the Plastic Surgery Foundation (PSF), and FDA. Health care providers can continue to submit case reports of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) to PROFILE as well.
Next, we turn to this March 6, 2023, MedPage Today news report, “Cases of Breast Implant-Associated Lymphoma Continue to Accumulate”, which provided updates on the number of breast implant-associated lymphoma deaths and diagnoses in the US and worldwide.
As of late 2022, the American Society of Plastic Surgeons global tracking network had accumulated 1,333 cases of BIA-ALCL worldwide and 35 associated deaths. The total included 402 cases and eight deaths in the U.S. The FDA has received information on 59 deaths, said Kelly K. Hunt, MD, of the University of Texas MD Anderson Cancer Center in Houston, during the Miami Breast Cancer Conference.
We continue to handle cases of breast implant-associated lymphoma, and we offer a Free Case Evaluation for women diagnosed with BIA-ALCL.[Read article in full at original source]